IL6 and ulcerative colitis: The results showed that IL-6, IL-8, hs- CRP and TNF-α were lower in the experimental group than those in the control group (P < 0.05), suggesting that mesalazine plus somatostatin and bifid triple viable capsules can effectively reduce the plasma inflammatory factor levels in ulcerative colitis patients.